Typical changes in the lungs of children with covid-19, atypical treatment

DOI: https://dx.doi.org/10.18565/pharmateca.2021.1.58-67

A.S. Polyakova, M.D. Bakradze, I.L. Mityushin, I.L. Chashchina, A.A. Tkacheva

National Medical Research Center for Children’s Health, Moscow
The article highlights the dynamics of global approaches to the treatment of a new coronavirus infection and presents 5 clinical cases of the course of COVID-19 in children in the Clinic of the National Medical Research Center for Children’s Health, which required intensive treatment, but in some cases the course of this infection did not require a specific approach in the presence of significant changes in the lungs. Based on updated world data and our own experience, the Clinic has made changes to the treatment protocols for children with moderate to severe COVID-19, including a short course of systemic glucocorticosteroids, as well as low molecular weight heparin. The success of this approach was the starting point for its inclusion in the new, second version of the guidelines for the treatment of COVID-19 in children dated 07/03/2020.
Keywords: COVID-19, SARS-CoV-2 coronavirus, systemic glucocorticosteroids, low molecular weight heparin

About the Autors

Corresponding author: Anastasia S. Polyakova, Cand. Sci. (Med.), Pediatrician, Department of Diagnostics and Rehabilitation Treatment, National Medical Research Center for Children’s Health, Moscow, Russia; tel.: +7 (495) 967-14-21; darmanyan@nczd.ru
Address: build. 1, 2 Lomonosovsky Prospect, Moscow 119991, Russian Federation

Бионика Медиа